Aug. 28 Company Quick Takes: Amgen to appeal Repatha ruling and EcoR1 buys Woodford’s stake in Prothena; plus DarwinHealth-Celgene, CRISPR IP, Trevena and Shink

Repatha patents invalid, court finds
Amgen Inc. (NASDAQ:AMGN) said it will appeal after a federal court found that its patents covering anti-PCSK9 mAb Repatha evolocumab are invalid on the basis of lack of enablement. The U.S. District Court for the District of Delaware ruled in favor of Sanofi

Read the full 473 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE